SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Tularik Inc. (TLRK) -- Ignore unavailable to you. Want to Upgrade?

To: mopgcw who wrote (148)4/8/2002 9:38:22 PM
From: scaram(o)uche  Respond to of 598
 
On paper.

At this market cap, I wonder what they picture as "the escape". T67 toxicity? Big deal. The aforementioned potential for cannibalism? If so, lack of vision.

One bit of obesity/lipid disorder news, and the company will suddenly look cheap, cheap, cheap.

I suspect that they're merely counting on non-earth shaking data at ASCO, combined with the soft underbelly of any biotech at MC:cash of >3.

Strange short, IMO.



To: mopgcw who wrote (148)4/10/2002 5:23:20 PM
From: scaram(o)uche  Read Replies (1) | Respond to of 598
 
>> Someone is making good money here in the immediate term.. <<

messages.yahoo.com

Don't ignore Avalon Research
by: CodeBrown_ 03/26/02 03:33 pm
Msg: 12414 of 12773

They were right on IMCL, AVIR, PCYC, and INHL. The longs always attack them as manipulators, bashers, and paid shorts. Most of the large brokerage houses only downgrade AFTER the FDA rejects an NDA.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News